NCT02273440已完成1 期
The Effects of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of a Single Dose of Theophylline in Healthy Male Volunteers (a Randomized, Double-blind, Placebo-controlled, Two-period, Two-way Crossover Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 主要终点
- Plasma levels of theophylline
研究概览
简要总结
To evaluate the effect of multiple doses of BIIL 284 BS on the pharmacokinetics of a single dose of theophylline.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Written informed consent signed and dated prior to participation into the study (including medication washout)
- •All volunteers in the study should be healthy males, aged 18-50 years (inclusive) and willing to use condoms until 60 days after the last dose
- •All volunteers should be within +- 20% of their ideal body weight (Metropolitan Scale, 1983)
- •Non-smokers (volunteers who have never smoked) or ex-smokers for at least one year with a smoking history, no greater than five pack-years (1 pack year = 20 cigarettes per day for one year)
- •Ability to comply with the concomitant therapy restrictions
- •Volunteers will be off all prescription drugs. O.T.C. drugs must be discontinued for at least two weeks prior to the first dose of study drug. If throughout the study, volunteers need any O.T.C. medication, the investigator will call the clinical monitor and this will be reviewed on a case-by-case bases. Restrictions for different medications apply
- •Volunteers will have no evidence of a clinically relevant concomitant disease based upon complete medical history, physician global assessment, complete physical examination, ECG, and clinical laboratory tests
排除标准
- •Viral respiratory tract infection, respiratory tract infection within the six weeks preceding the first day of dosing with study medication
- •Small of difficult to locate arm or hand veins that would impair the clinician's ability to draw blood samples or to place a venous catheter
- •Volunteers with a known drug or alcohol dependence (presence of dependency for 10 years) or who drink more than 60 g of alcohol per day
- •History of significant allergic reactions to drugs or sensitivity to aspirin or positive drug screen
- •Use of an investigational new drug in the preceding 3 months or six half-lives (whichever is greater) prior to the first screen at Visit 1
- •Donation of blood during the preceding 3 months of Visit 1
- •Volunteers receiving hyposensitization therapy whom are not on a stable dose for the last three months before Visit 1
- •Volunteers with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
- •Volunteers with disease of the central nervous system (such as epilepsy) or with psychiatric disorders
- •Volunteers with known history of orthostatic hypotension, fainting spells or blackouts
- •Volunteers with chronic or relevant acute infections
- •Volunteers with history of allergy/hypersensitivity (including drug allergy) with is deemed relevant to the trial as judged by the investigator
- •Volunteers with eosinophilia > 7%
- •Volunteers who received any other drugs which might influence the results of the trial during the week previous to the start of the study
- •Volunteers who participated in excessive physical activities (e.g. competitive sports) within the last week before the study
研究组 & 干预措施
BIIL 284 BS with theophylline
Experimental
干预措施: BIIL 284 BS (Drug)
BIIL 284 BS with theophylline
Experimental
干预措施: Theophylline (Drug)
Placebo with theophylline
Placebo Comparator
干预措施: Theophylline (Drug)
Placebo with theophylline
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Plasma levels of theophylline
时间窗: up to 72 hours after theophylline administration
Area under the curve from zero extrapolated to infinity (AUC0-infinity)
时间窗: up to 72 hours after theophylline administration
Peak plasma concentration (Cmax) for theophylline
时间窗: up to 72 hours after theophylline administration
次要结局
- Time to peak plasma concentration (tmax)(up to 72 hours after theophylline administration)
- Total mean residence time (MRTtot)(up to 72 hours after theophylline administration)
- Number of patients with clinically significant findings in vital signs(up to 3 days after last drug administration)
- Number of patients with clinically significant findings in 12-lead ECG(up to 3 days after last drug administration)
- Number of patients with clinically significant findings in laboratory tests(up to 3 days after last drug administration)
- Number of patients with adverse events(up to 5 days after last theophylline administration)
- Terminal half-life (t1/2)(up to 72 hours after theophylline administration)
- Area under the concentration time curve at steady state (AUC,ss) for BIIL 315 ZW(up to 72 hours after theophylline administration)
- Peak plasma concentration at steady state (Cmax,ss) for BIIL 315 ZW(up to 72 hours after theophylline administration)
- Total clearance after oral administration (CLtot/F)(up to 72 hours after theophylline administration)
- Volume of distribution during terminal phase after oral administration (Vz/F)(up to 72 hours after theophylline administration)
研究者
相似试验
已完成
1 期
Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male SubjectsHealthyNCT02268149Boehringer Ingelheim20
已完成
1 期
A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the BloodHealthyNCT05613777Boehringer Ingelheim19
已完成
1 期
Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female VolunteersHIV InfectionsNCT01374802Boehringer Ingelheim14
已完成
1 期
Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS for HandiHaler® in Healthy Male VolunteersHealthyNCT02216461Boehringer Ingelheim36
已完成
1 期
Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy VolunteersHepatic InsufficiencyNCT02265627Boehringer Ingelheim32